메뉴 건너뛰기




Volumn 25, Issue 30, 2007, Pages 4821-4828

Rational selection of patients for antibacterial prophylaxis after chemotherapy

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LEVOFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT; OFLOXACIN;

EID: 36049026740     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.7395     Document Type: Article
Times cited : (47)

References (23)
  • 1
    • 24344445873 scopus 로고    scopus 로고
    • Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas
    • Cullen M, Steven N, Billingham L, et al: Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988-998, 2005
    • (2005) N Engl J Med , vol.353 , pp. 988-998
    • Cullen, M.1    Steven, N.2    Billingham, L.3
  • 2
    • 24344471724 scopus 로고    scopus 로고
    • Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia
    • Bucaneve G, Micozzi A, Menichetti F, et al: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977-987, 2005
    • (2005) N Engl J Med , vol.353 , pp. 977-987
    • Bucaneve, G.1    Micozzi, A.2    Menichetti, F.3
  • 3
    • 33750042267 scopus 로고    scopus 로고
    • Antibiotic Prophylaxis in Neutropenic Patients: New evidence, practical decisions
    • Leibovici L, Paul M, Cullen MH, et al: Antibiotic Prophylaxis in Neutropenic Patients: New evidence, practical decisions. Cancer 107:1743-1751, 2006
    • (2006) Cancer , vol.107 , pp. 1743-1751
    • Leibovici, L.1    Paul, M.2    Cullen, M.H.3
  • 4
    • 0028986117 scopus 로고
    • Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin
    • Carratalá J, Fernandez-Sevilla A, Tubau F, et al: Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557-560, 1995
    • (1995) Clin Infect Dis , vol.20 , pp. 557-560
    • Carratalá, J.1    Fernandez-Sevilla, A.2    Tubau, F.3
  • 5
    • 0028344856 scopus 로고
    • Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia
    • Cometta A, Calandra T, Bille J, et al: Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330:1240-1241, 1994
    • (1994) N Engl J Med , vol.330 , pp. 1240-1241
    • Cometta, A.1    Calandra, T.2    Bille, J.3
  • 6
    • 0024809041 scopus 로고
    • Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis
    • Kern W, Linzmeier K, Kurrle E: Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection 17:396-397, 1989
    • (1989) Infection , vol.17 , pp. 396-397
    • Kern, W.1    Linzmeier, K.2    Kurrle, E.3
  • 7
    • 16844386485 scopus 로고    scopus 로고
    • Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia
    • Kern WV, Klose K, Jellen-Ritter AS, et al: Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24:111-118, 2005
    • (2005) Eur J Clin Microbiol Infect Dis , vol.24 , pp. 111-118
    • Kern, W.V.1    Klose, K.2    Jellen-Ritter, A.S.3
  • 8
    • 0027435085 scopus 로고
    • Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin
    • McWhinney PH, Patel S, Whiley RA, et al: Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother 37:2493-2495, 1993
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 2493-2495
    • McWhinney, P.H.1    Patel, S.2    Whiley, R.A.3
  • 10
    • 41049093347 scopus 로고
    • The combination of estimates from different experiments
    • Cochran WG: The combination of estimates from different experiments. Biometrics 10:101-129, 1954
    • (1954) Biometrics , vol.10 , pp. 101-129
    • Cochran, W.G.1
  • 11
    • 0036467835 scopus 로고    scopus 로고
    • Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
    • Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 727-731
    • Holmes, F.A.1    O'Shaughnessy, J.A.2    Vukelja, S.3
  • 12
    • 0035189248 scopus 로고    scopus 로고
    • Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study
    • Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al: Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359-1368, 2001
    • (2001) Ann Oncol , vol.12 , pp. 1359-1368
    • Tjan-Heijnen, V.C.1    Postmus, P.E.2    Ardizzoni, A.3
  • 13
    • 32944482839 scopus 로고    scopus 로고
    • Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study
    • Timmer-Bonte JN, de Boo TM, Smit HJ, et al: Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study. J Clin Oncol 23:7974-7984, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 7974-7984
    • Timmer-Bonte, J.N.1    de Boo, T.M.2    Smit, H.J.3
  • 14
    • 14544270307 scopus 로고    scopus 로고
    • First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
    • Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 1178-1184
    • Vogel, C.L.1    Wojtukiewicz, M.Z.2    Carroll, R.R.3
  • 15
    • 0345604387 scopus 로고    scopus 로고
    • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate grade non-Hodgkin lymphoma
    • Lyman GH, Delgado DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate grade non-Hodgkin lymphoma. Cancer 98:2402-2409, 2003
    • (2003) Cancer , vol.98 , pp. 2402-2409
    • Lyman, G.H.1    Delgado, D.J.2
  • 16
    • 33645550926 scopus 로고    scopus 로고
    • First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: Results from a prospective nationwide study
    • abstr 2210
    • Crawford J, Wolff DA, Culakova E, et al: First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: Results from a prospective nationwide study. Proc Am Soc Hematol 104, 2004 (abstr 2210)
    • (2004) Proc Am Soc Hematol , vol.104
    • Crawford, J.1    Wolff, D.A.2    Culakova, E.3
  • 17
    • 33748442136 scopus 로고    scopus 로고
    • Febrile neutropenia: Highlighting the role of prophylactic antibiotics and G-CSF during standard dose chemotherapy for solid tumors
    • Timmer-Bonte JN, Tjan-Heijnen VC: Febrile neutropenia: Highlighting the role of prophylactic antibiotics and G-CSF during standard dose chemotherapy for solid tumors. Anticancer Drugs 17:881-889, 2006
    • (2006) Anticancer Drugs , vol.17 , pp. 881-889
    • Timmer-Bonte, J.N.1    Tjan-Heijnen, V.C.2
  • 18
    • 33845876873 scopus 로고    scopus 로고
    • Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: Systematic review and metaanalysis
    • Gafter-Gvili A, Paul M, Fraser A, et al: Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: Systematic review and metaanalysis. J Antimicrob Chemother 59:5-22, 2007
    • (2007) J Antimicrob Chemother , vol.59 , pp. 5-22
    • Gafter-Gvili, A.1    Paul, M.2    Fraser, A.3
  • 19
    • 0031943040 scopus 로고    scopus 로고
    • Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom
    • Fossa SD, Kaye SB, Mead GM, et al: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716-724, 1998
    • (1998) J Clin Oncol , vol.16 , pp. 716-724
    • Fossa, S.D.1    Kaye, S.B.2    Mead, G.M.3
  • 20
  • 21
    • 0347985317 scopus 로고    scopus 로고
    • Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management
    • Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 100:228-237, 2004
    • (2004) Cancer , vol.100 , pp. 228-237
    • Crawford, J.1    Dale, D.C.2    Lyman, G.H.3
  • 22
    • 36049051974 scopus 로고    scopus 로고
    • Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy in breast cancer patients
    • suppl; abstr 8008, 731s
    • Von Minckwitz G, Blohmer J, Löhr A et al: Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy in breast cancer patients. J Clin Oncol 23:731s, 2005 (suppl; abstr 8008)
    • (2005) J Clin Oncol , vol.23
    • Von Minckwitz, G.1    Blohmer, J.2    Löhr, A.3
  • 23
    • 33746007143 scopus 로고    scopus 로고
    • Cost-effectiveness of adding granulocyte colonystimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer
    • Timmer-Bonte JN, Adang EM, Smit HJ, et al: Cost-effectiveness of adding granulocyte colonystimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 24:2991-2997, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 2991-2997
    • Timmer-Bonte, J.N.1    Adang, E.M.2    Smit, H.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.